Charvat H, Goto A, Goto M, et al. Impact of population aging on trends in diabetes prevalence: a meta-regression analysis of 160,000 Japanese adults. J Diabetes Investig. 2015;6(5):533–42.
CAS
PubMed
PubMed Central
Article
Google Scholar
International Diabetes Federation (IDF) Western Pacific members. Japan. 2018. https://www.idf.org/our-network/regions-members/western-pacific/members/105-japan.html. Accessed 5 May 2018.
Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302.
CAS
PubMed
Article
Google Scholar
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98.
PubMed
Article
Google Scholar
Guthrie RM. Evolving therapeutic options for type 2 diabetes mellitus: an overview. Postgrad Med. 2012;124(6):82–9.
PubMed
Article
Google Scholar
Marin-Penalver JJ, Martin-Timon I, Sevillano-Collantes C, Del Canizo-Gomez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7(17):354–95.
PubMed
PubMed Central
Article
Google Scholar
Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–9.
CAS
PubMed
Article
Google Scholar
Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17(10):984–93.
CAS
PubMed
Article
Google Scholar
Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother. 2014;15(11):1501–15.
CAS
PubMed
Article
Google Scholar
Kadowaki T, Haneda M, Inagaki N, et al. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. Adv Ther. 2015;32(4):306–18.
CAS
PubMed
Article
Google Scholar
Kaku K, Maegawa H, Tanizawa Y, et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014;5(2):415–33.
CAS
PubMed
PubMed Central
Article
Google Scholar
Kashiwagi A, Kazuta K, Yoshida S, Nagase I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(4):382–91.
CAS
PubMed
Article
Google Scholar
Seino Y, Inagaki N, Haneda M, et al. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2015;6(4):443–53.
CAS
PubMed
PubMed Central
Article
Google Scholar
Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014;30(7):1245–55.
CAS
PubMed
Article
Google Scholar
Goda M, Yamakura T, Sasaki K, Tajima T, Ueno M. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan. Curr Med Res Opin. 2018;34(2):319–27.
CAS
PubMed
Article
Google Scholar
Nakamura I, Maegawa H, Tobe K, Tabuchi H, Uno S. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Expert Opin Pharmacother. 2018;19(3):189–201.
CAS
PubMed
Article
Google Scholar
Utsunomiya K, Shimmoto N, Senda M, et al. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: a post-marketing study (J-STEP/EL Study). J Diabetes Investig. 2017;8(6):766–75.
CAS
PubMed
PubMed Central
Article
Google Scholar
Yokote K, Terauchi Y, Nakamura I, Sugamori H. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opin Pharmacother. 2016;17(15):1995–2003.
CAS
PubMed
Article
Google Scholar
Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2–10.
Article
Google Scholar
Medical Data Vision Co. Ltd (MDV). Introducing MDV database. https://www.mdv.co.jp/solution/pharmaceutical/english/. Accessed 27 Apr 2018.
Kyowa Kikaku Ltd. Medi-Trend (out-of-hospital prescription database system). Accessed at Kyowa Kikaku Ltd. at https://www.kk-kyowa.co.jp/medical_prescription.html. Accessed 29 Aug 2018.
Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20(5):413–9.
PubMed
PubMed Central
Article
Google Scholar
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.
CAS
PubMed
Article
Google Scholar
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.
PubMed
Article
Google Scholar
van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626–33.
PubMed
Article
Google Scholar
Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15–23.
PubMed
PubMed Central
Google Scholar
Glasheen WP, Renda A, Dong Y. Diabetes Complications Severity Index (DCSI)—update and ICD-10 translation. J Diabetes Complicat. 2017;31(6):1007–13.
PubMed
Article
Google Scholar
Wilke T, Mueller S, Groth A, et al. Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:14.
PubMed
PubMed Central
Article
Google Scholar
Hankins M, Tsai K, Kim J, Hammar N. Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany. Diabetes Res Clin Pract. 2017;125:29–38.
PubMed
Article
Google Scholar
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018;393:31.
PubMed
Article
Google Scholar
Yamana H, Moriwaki M, Horiguchi H, et al. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27(10):476–82.
PubMed
PubMed Central
Article
Google Scholar